NRXP ▼ -0.3% - NRx Pharmaceuticals, Inc. $NRXP - GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) NRx Pharmaceuticals declined 0.3% despite securing European patent rights for GNK-301, its investigational ALS treatment candidate. The patent award strengthens the company's intellectual property position for the drug in Europe, though the modest stock decline suggests investors may have already priced in the milestone or viewed it as an incremental development for a company with a clinical-stage asset. 14-SEP-2026 07:01 AM ET